Jorge Santos da Silva - 07 Jan 2026 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role: Chief Executive Officer, Director
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva
Issuer symbol: MLTX
Transactions as of: 07 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 16:01:04 UTC
Previous filing: 22 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Santos da Silva Jorge	Chief Executive Officer, Director	C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND	/s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva	09 Jan 2026	0001920509

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLTX	Stock Option (Right to Buy)	Award	$0	+520,342		$0.000000	520,342	07 Jan 2026	Class A ordinary shares, par value $0.0001 per share	520,342	$11.29	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.